NovaBridge Biosciences (NBP) Capital Expenditures (2019 - 2024)

NovaBridge Biosciences (NBP) posted quarterly Capital Expenditures of -$38000.0 for Q4 2024, down 3700.0% on a QoQ basis from -$1000.0 in Q3 2024.

NovaBridge Biosciences (NBP) Capital Expenditures (2019 - 2024) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Capital Expenditures for 3 consecutive years, with -$38000.0 the latest figure, recorded in Q4 2024.

Quarterly Capital Expenditures changed N/A year-over-year to -$38000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$39000.0 (down 103.2% YoY) and the FY2025 annual result came in at -$7000.0, up 85.42% from the prior year.
Capital Expenditures slipped to -$38000.0 in Q4 2024 per NBP's latest filing, from -$1000.0 in the prior quarter.
Over the last five years, Capital Expenditures for NBP reached as high as $1.9 million in Q4 2020 and fell as low as -$668360.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	NovaBridge Biosciences	389.86 Mn	389.86 Mn	-	-

Download Data